Recruiting

Comparison of Phaco Surgery With Goniosynechialysis Versus Trabeculectomy in Glaucoma Treatment

The goal of this clinical trial is to learn whether phacoemulsification combined with goniosynechialysis (Phaco-GSL) is as effective and safe as trabeculectomy in treating patients with primary angle-closure glaucoma. The main questions it aims to answer are: * Does Phaco-GSL provide similar or better intraocular pressure (IOP) control compared to trabeculectomy? * What are the rates of postoperative complications or adverse events between the two surgical approaches? * How do the two procedures compare in terms…

ClinicalTrials.gov IDNCT06952153
PhaseNA
Enrollment82
SponsorUniversity of Medicine and Pharmacy at Ho Chi Minh City
Age40 Years
SexALL
I'm interested View official listing

Conditions studied

Primary Angle Closure Glaucoma

About this study

The goal of this clinical trial is to learn whether phacoemulsification combined with goniosynechialysis (Phaco-GSL) is as effective and safe as trabeculectomy in treating patients with primary angle-closure glaucoma. The main questions it aims to answer are: * Does Phaco-GSL provide similar or better intraocular pressure (IOP) control compared to trabeculectomy? * What are the rates of postoperative complications or adverse events between the two surgical approaches? * How do the two procedures compare in terms of visual acuity recovery and need for glaucoma medications? Researchers will compare Phaco-GSL to trabeculectomy to determine which procedure offers better overall outcomes for patients with angle-closure glaucoma. Participants will: Be randomly assigned to undergo either Phaco-GSL or trabeculectomy Attend scheduled follow-up visits at regular intervals (e.g., 1 week, 1 month, 3 months, 6 months, 12 months) for eye exams and pressure checks

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Age ≥ 40 years * Peripheral anterior synechiae (PAS) \>180° * Glaucomatous optic neuropathy with visual field loss * Intraocular pressure (IOP) \> 21 mmHg despite medication * Ability to consent and comply with follow-up * Cataract grade 1 to 3 according to LOCS III * Best corrected visual acuity (BCVA) ≥ 0.3 logMAR (equivalent to 20/40 Snellen or worse) Exclusion Criteria: * Very advanced glaucoma (only light perception vision) * Secondary angle-closure etiologies * Prior ocular surgeries or laser peripheral iridotomy (PI) * Allergy to 5-fluorouracil (5-FU), if used postoperatively * Irreversible corneal disease * Chronic corticosteroid use * Poor follow-up compliance * Cataract grade 4 or 5 (LOCS III) * Phacomorphic, phacolytic, or subluxated cataracts

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.